Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0
Law I (1), Albert NL (2), Arbizu J (3), Boellaard R (4,5), Drzezga A (6), Galldiks N (7,8), la Fougère C (9), Langen KJ (8,10), Lopci E (11), Lowe V (12), McConathy J (13), Quick HH (14), Sattler B (15), Schuster DM (16), Tonn JC (17), Weller M (18).
(1) Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, University of Copenhagen, 9, Blegdamsvej, 2100-DK, Copenhagen Ø, Denmark.
(2) Department of Nuclear Medicine, Ludwig-Maximilians-University, Munich, Germany.
(3) Department of Nuclear Medicine, Clínica Universidad de Navarra, University of Navarre, Pamplona, Spain.
(4) Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, The Netherlands.
(5) Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands.
(6) Department of Nuclear Medicine, University Hospital Cologne, Cologne, Germany.
(7) Department of Neurology, University Hospital Cologne, Cologne, Germany.
(8) Institute of Neuroscience and Medicine (INM-3, -4), Forschungszentrum Julich, Julich, Germany.
(9) Division of Nuclear Medicine and Clinical Molecular Imaging, Department of Radiology, University of Tübingen, Tübingen, Germany.
(10) Department of Nuclear Medicine, RWTH University Aachen, Aachen, Germany.
(11) Department of Nuclear Medicine, Humanitas Clinical and Research Hospital, Rozzano, Italy.
(12) Department of Radiology, Nuclear Medicine, Mayo Clinic, Rochester, MN, USA.
(13) Division of Molecular Imaging and Therapeutics, University of Alabama at Birmingham, Birmingham, AL, USA.
(14) High-Field and Hybrid MR Imaging, University Hospital Essen, Essen, Germany.
(15) Department for Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany.
(16) Division of Nuclear Medicine and Molecular Imaging, Department of Radiology and Imaging Sciences, Emory University, Atlanta, GA, USA.
(17) Department of Neurosurgery, Ludwig-Maximilians-University Munich, Munich, Germany.
(18) Department of Neurology, University Hospital Zurich, Zurich, Switzerland.
These joint practice guidelines, or procedure standards, were developed collaboratively by the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Neurooncology (EANO), and the working group for Response Assessment in Neurooncology with PET (PET-RANO).
Brain PET imaging is being increasingly used to supplement MRI in the clinical management of glioma. The aim of these standards/guidelines is to assist nuclear medicine practitioners in recommending, performing, interpreting and reporting the results of brain PET imaging in patients with glioma to achieve a high-quality imaging standard for PET using FDG and the radiolabelled amino acids MET, FET and FDOPA.
This will help promote the appropriate use of PET imaging and contribute to evidence-based medicine that may improve the diagnostic impact of this technique in neurooncological practice. The present document replaces a former version of the guidelines published in 2006 (Vander Borght et al. Eur J Nucl Med Mol Imaging. 33:1374-80, 2006), and supplements a recent evidence-based recommendation by the PET-RANO working group and EANO on the clinical use of PET imaging in patients with glioma (Albert et al. Neuro Oncol. 18:1199-208, 2016). The information provided should be taken in the context of local conditions and regulations.
CITATIONO Eur J Nucl Med Mol Imaging. 2018 Dec 5. doi: 10.1007/s00259-018-4207-9.